Evidence map›Paper›PMID 8564234›Full record

ArticleBritish journal of pharmacology1995

Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation.

W S Lee, V Limmroth, C Ayata, F M Cutrer, C Waeber, X Yu, M A Moskowitz

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 88 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. α6GABANeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  6. Article
  7. N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Article
  8. Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019
    Article
  9. The α6 subunit-containing GABANeuropharmacology · 2018
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Homocysteine causes cerebrovascular leakage in mice.American journal of physiology. Heart and circulatory physiology · 2006
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

W S LeeMassachusetts General Hospital, Stroke and Neurovascular Regulation, Charlestown 02129, USA.
V Limmroth
C Ayata
F M Cutrer
C Waeber
X Yu
M A Moskowitz
Massachusetts General Hospital · US

Funding

TRIGEMINAL NERVE: CONTROL OF THE BRAIN VASCULATURER01NS021558 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI MOSKOWITZ, MICHAEL A · 1985 to 1995
–
NINDS NIH HHS NS21558
6 · The paper itself

Abstract

1. The GABA transaminase inhibitor and activator of glutamic acid decarboxylase, valproic acid is being used for the treatment of migraine. Its mechanism of action is unknown. We tested the effects of sodium valproate and GABAA-agonist muscimol on dural plasma protein ([125I]-bovine serum albumin) extravasation evoked by either unilateral trigeminal ganglion stimulation (0.6 mA, 5 ms, 5 Hz, 5 min) or substance P (SP) administration (1 nmol kg-1,i.v.) in anaesthetized Sprague-Dawley rats. 2. Intraperitoneal (i.p.) injection of sodium valproate or muscimol, but not baclofen (< or = 10 mg kg-1, i.p.) dose-dependently reduced dural plasma protein extravasation caused either by electrical trigeminal stimulation (ED50: 6.6 +/- 1.4 mg kg-1, i.p., and 58 +/- 18 micrograms kg-1, i.p. for valproate or muscimol, respectively) or by intravenous substance P administration (ED50: 3.2 +/- 1.4 mg kg-1, i.p. and 385 +/- 190 micrograms kg-1, i.p. for valproate or muscimol, respectively). 3. Valproate (6.6 mg kg-1, i.p.) or muscimol (58 micrograms kg-1, i.p.) had no effect on mean arterial blood pressure or heart rate when measured for 30 min after i.p. administration. 4. The GABAA-antagonist bicuculline (0.01 mg kg-1, i.p.) completely reversed the effect of valproate and muscimol on plasma extravasation following electrical stimulation or substance P administration, whereas the GABAB-receptor antagonist, phaclofen (0.01-1 mg kg-1, i.p.) did not. Bicuculline or phaclofen, given alone, did not alter the plasma extravasation response after either electrical stimulation or SP administration. 5. Valproate decreased plasma extravasation following substance P administration in adult animals, neonatally treated with capsaicin by a bicuculline-reversible mechanism. This suggests that GABAA receptors are not found primarily on those afferent neurones or fibres which are sensitive to capsaicin treatment in neonatal rats.6. We conclude that sodium valproate blocks plasma extravasation in the meninges through GABAA mediated postjunctional receptors probably within the meninges. The dosages required are comparable to those used clinically. Agonists and modulators at the GABAA receptor may become useful for the development of selective therapeutic agents for migraine and cluster headache.

Indexed as

Extravasation of Diagnostic and Therapeutic MaterialsAnimalsBaclofenBlood PressureCapillary PermeabilityCapsaicinDura MaterElectric StimulationGABA AgentsGABA AgonistsGABA-A Receptor AgonistsGABA-A Receptor AntagonistsHeart RateIodine RadioisotopesMaleMuscimolBaclofenCapsaicinGABA AgentsGABA AgonistsGABA-A Receptor AgonistsGABA-A Receptor AntagonistsIodine RadioisotopesMuscimolReceptors, GABA-ASerum Albumin, BovineSubstance PValproic Acid

Identifiers

PMID8564234
PMCPMC1908914
OpenAlexW2065223010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.